Christine Messmer PC Acquires Shares of 17,072 Merck & Co., Inc. $MRK

Key Points

• Christine Messmer PC acquired a new stake of 17,072 shares of Merck in Q4, valued at about $1.797 million and representing roughly 1.2% of its portfolio (its 20th-largest holding).
• Merck’s Q1 results beat expectations with revenue of $16.29 billion and EPS of ($1.28) vs. consensus ($1.47), and management set FY‑2026 guidance of 5.040–5.160 EPS (analysts average ~4.9 EPS).
• Senior insiders sold notable stock positions (CEO Robert M. Davis: 47,434 shares; CFO Caroline Litchfield: 41,997 shares), with insiders selling ~320,176 shares (~$38.3M) over the last three months while institutional investors own about 76.07% of Merck.

Christine Messmer PC acquired a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 17,072 shares of the company's stock, valued at approximately $1,797,000. Merck & Co., Inc. accounts for approximately 1.2% of Christine Messmer PC's portfolio, making the stock its 20th biggest holding.

A number of other hedge funds have also recently modified their holdings of the company. Barnes Dennig Private Wealth Management LLC boosted its stake in shares of Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after purchasing an additional 266 shares in the last quarter. United Financial Planning Group LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $31,000. Wealth Watch Advisors INC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $34,000. Dunhill Financial LLC boosted its stake in shares of Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company's stock valued at $35,000 after purchasing an additional 190 shares in the last quarter. Finally, Silicon Valley Capital Partners boosted its stake in shares of Merck & Co., Inc. by 160.5% during the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company's stock valued at $35,000 after purchasing an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Trading Up 0.8%

Shares of NYSE MRK opened at $113.05 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The firm's 50 day moving average price is $117.69 and its 200-day moving average price is $107.70. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a market cap of $279.21 billion, a PE ratio of 31.84, a P/E/G ratio of 2.27 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. The firm had revenue of $16.29 billion during the quarter, compared to analysts' expectations of $15.85 billion. During the same period in the previous year, the company earned $2.22 earnings per share. The firm's quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 4.9 EPS for the current fiscal year.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — revenue of $16.29B, EPS ahead of consensus, and management maintained/raised FY‑2026 guidance and reiterated growth drivers from oncology and new launches. MRK Q1 Deep Dive
• Positive Sentiment: Pipeline and M&A boost long‑term thesis — recent FDA approval of the HIV regimen IDVYNSO, KEYTRUDA priority reviews and the Terns acquisition (adds TERN‑701) support upside beyond Keytruda. Analysts and bulls point to these as offsetting Patent risks. Pipeline & Terns Acquisition
• Positive Sentiment: Analyst and media support — major firms (Wells Fargo, BMO) reaffirm buy ratings and commentators such as Jim Cramer highlighted the quarter as a turning point, which helps sentiment. Wells Fargo Buy Rating BMO Buy Rating Jim Cramer on MRK
• Neutral Sentiment: Institutional commentary — Baron Capital highlighted MRK in its Q1 letter as an investment case, reflecting continued institutional interest but not immediate catalyst. Baron Capital Letter
• Negative Sentiment: Technical/price risk — chart analysts flag a confirmed double‑top breakdown and moving‑average resistance that could open a deeper correction, increasing short‑term downside risk despite fundamentals. Double Top Technical Risk
• Negative Sentiment: Sector rotation and shorter‑term profit‑taking — some sell pressure in pharma after strong earnings days for the sector has weighed on MRK intermittently, tempering the rally. Sector Sentiment Note

Insider Activity

In other news, CEO Robert M. Davis sold 47,434 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares of the company's stock, valued at $52,362,780.08. The trade was a 9.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Caroline Litchfield sold 41,997 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the transaction, the chief financial officer directly owned 90,192 shares of the company's stock, valued at $10,787,865.12. The trade was a 31.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 320,176 shares of company stock valued at $38,281,735 over the last three months. Corporate insiders own 0.17% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on MRK shares. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 17th. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a "neutral" rating in a research note on Wednesday, February 4th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Finally, UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.